ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Capecitabine

Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.

Drug pageCapecitabine: every studyMany companies study it; this page follows only the 72 they lead. All 947 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 12, 200472 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche430 open or runningphase 4since Jul 12, 2004May 2, 2000none ahead
Sanofiits history only90 open or runningphase 3since Apr 20, 2004Apr 20, 2004none ahead
R-Pharmits history only60 open or runningphase 3since Mar 26, 2004Nov 12, 2002none ahead
Novartisits history only41 open or runningphase 3since Jul 26, 2007Jul 26, 2007Apr 14, 2027phase 2 · NCT06247995
Qilu Pharmaceuticalits history only21 open or runningphase 2since Jun 1, 2024Feb 10, 2018none ahead
Academy Military Medical Science, Chinaits history only10 open or runningphase 2since Jul 14, 2008Jul 14, 2008none ahead
Bio-Cancer Treatment Internationalits history only10 open or runningphase 2since Mar 14, 2014Mar 14, 2014none ahead
EBG MedAustronits history only11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
iOMEDICOits history only10 open or runningphase 4since Aug 28, 2014Aug 28, 2014none ahead
NovoCureits history only10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead

Also a collaborator on its studies: Exelixis, Clovis Oncology, Johnson & Johnson, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Zai Lab, Chengdu Biostar Pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and Yakult Honsha.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 27 studies since May 2, 2000.

  1. Jun 1, 2010Phase 2 study in Colorectal NeoplasmsNCT01135498 · 90 enrolled · Spain
  2. Oct 22, 2010Phase 2 study in Colorectal NeoplasmsNCT01227707 · 43 enrolled · Italy
  3. Feb 3, 2011Phase 2 study in Breast NeoplasmsNCT01290718 · 4 enrolled · Taiwan
  4. Oct 10, 2011Phase 3 study in Stomach NeoplasmsNCT01450696 · 296 enrolled · United States, Australia, Bosnia and Herzegovina and more
  5. Dec 10, 2012Phase 2 study in Stomach NeoplasmsNCT01748773 · 34 enrolled · Turkey
  6. Dec 3, 2013Phase 2 study in Liver NeoplasmsNCT02013830 · 45 enrolled · Australia, Hong Kong, Singapore and more
  7. Nov 11, 2014Phase 2 study in Colorectal NeoplasmsNCT02291289 · 1,044 enrolled · Argentina, Belgium, Bosnia and Herzegovina and more
  8. Sep 24, 20152 phase 3 studies in Stomach NeoplasmsNCT02560974, NCT02563054
  9. Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsNCT02565641 · 63 enrolled · Korea, Republic of
  10. Oct 1, 20152 phase 4 studies in Colorectal NeoplasmsNCT02567331, NCT02581423
  11. Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularNCT02576964 · 16 enrolled · China, Taiwan, Thailand
  12. Nov 16, 2015Phase 2 study in Nasopharyngeal NeoplasmsNCT02608073 · 45 enrolled · Hong Kong, Indonesia, Malaysia and more
  13. Feb 25, 2016Phase 2 study in Rectal NeoplasmsNCT02694718 · 60 enrolled · Switzerland
  14. Jul 25, 2016Phase 2 study in Breast NeoplasmsNCT02846428 · 182 enrolled · France

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
FluorouracilruleSanofiphase 482
TegafurruleOtsukaphase 325

Studies

All 43 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02846428Breast Neoplasms · France2CompletedDec 2011182
NCT02694718Rectal Neoplasms · Switzerland2CompletedAug 200660
NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more2CompletedNov 200945
NCT02581423Colorectal Neoplasms · Bulgaria4CompletedMar 200763
NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand2CompletedNov 200816
NCT02567331Colorectal Neoplasms · Bulgaria4CompletedApr 200628
NCT02565641Pancreatic Neoplasms · Korea, Republic of2CompletedSep 200663
NCT02563054Stomach Neoplasms · Argentina, Belize, Brazil and more3CompletedAug 2010316
NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedNov 20121,035
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedMay 31, 20191,044
NCT02013830Liver Neoplasms · Australia, Hong Kong, Singapore and more2CompletedMar 200845
NCT01748773Stomach Neoplasms · Turkey2CompletedAug 21, 201534
NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more3TerminatedFeb 2015296
NCT01290718Breast Neoplasms · Taiwan2TerminatedDec 20124
NCT01227707Colorectal Neoplasms · Italy2CompletedAug 201043
NCT01135498Colorectal Neoplasms · Spain2CompletedApr 201090
NCT01130337Stomach Neoplasms · Spain2CompletedJun 201436
NCT01118377Brainstem Glioma · United States2CompletedJan 201345
NCT01077739Colorectal Neoplasms · Belgium2CompletedJan 201275
NCT01077726Breast Neoplasms · France2CompletedDec 20103
NCT00977379Breast Neoplasms · France2TerminatedFeb 201124
NCT00929240Breast Neoplasms · Brazil, China, Egypt and more3CompletedJun 2014287
NCT00925769Pancreatic Neoplasms · Austria1CompletedDec 201332
NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more2CompletedFeb 18, 201333
NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more2CompletedDec 201588
NCT00796718Colorectal Neoplasms · Slovakia2CompletedAug 201062
NCT00623805Colorectal Neoplasms · Turkey3CompletedMay 2012123
NCT00577031Colorectal Neoplasms · Italy4CompletedAug 2011205
NCT00576901Breast Neoplasms · Spain2TerminatedJun 200923
NCT00532948Glioma · United States1CompletedOct 201024
NCT00502671Colorectal Neoplasms · Russian Federation4CompletedMar 2012228
NCT00448136Neoplasms · France2CompletedNov 201183
NCT00345761Colorectal Neoplasms · Japan2CompletedOct 200864
NCT00121836Breast Neoplasms · United States4CompletedDec 2008109
NCT00118755Colorectal Neoplasms2CompletedApr 2009435
NCT00112918Colorectal Neoplasms · United States3CompletedJun 20103,451
NCT00087620Breast Neoplasms · United States4TerminatedOct 2004
NCT00077857Breast Neoplasms · United States, Bosnia and Herzegovina, China and more2CompletedMar 2010470
NCT00069121Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedApr 21, 20111,886
NCT00069095Colorectal Neoplasms · United States, Australia, Austria and more3CompletedJan 20062,035
NCT00022698Colorectal Neoplasms · United States2CompletedDec 200467
NCT00009737Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedApr 20041,987
NCT00005649Breast Neoplasms · United States2CompletedJul 4, 2002

How it is read

Names in the registry

  • “Capecitabine”, 62 entries
  • “capecitabine”, 16 entries
  • “capecitabine [Xeloda]”, 12 entries
  • “Utidelone in combination with capecitabine”, 3 entries
  • “Capecitabine [Xeloda]”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.